NCT_ID,Title,Sponsor,Status,Phase,Primary_Completion_Date,Estimated_Enrollment,Enrollment_Type,Conditions,Interventions,Start_Date,Estimated_Completion,Upcoming_Readout,Delay_Flag,Ticker,Market_Cap,Signal
NCT06292923,A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients,Tiziana Life Sciences LTD,RECRUITING,PHASE2,2025-11-01,54,ESTIMATED,Secondary Progressive Multiple Sclerosis,"Foralumab, Placebo",2023-11-15,2025-11-01,True,False,TLSA,230190032.0,Buy
